EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE Drug Patent Profile

Which patents cover Emtricitabine And Tenofovir Alafenamide Fumarate, and when can generic versions of Emtricitabine And Tenofovir Alafenamide Fumarate launch?

Emtricitabine And Tenofovir Alafenamide Fumarate is a drug marketed by Apotex, Lupin Ltd, and Macleods Pharms Ltd. and is included in three NDAs.

The generic ingredient in EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE is emtricitabine; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Alafenamide Fumarate

A generic version of EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE was approved as emtricitabine; tenofovir alafenamide fumarate by MACLEODS PHARMS LTD on April 7^th, 2026.

Summary for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	214053-001	May 17, 2024		DISCN	No	No
Macleods Pharms Ltd	EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	214216-001	Apr 7, 2026	AB	RX	No	No
Apotex	EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE	emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	214053-002	May 17, 2024		DISCN	No	No

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE Market Analysis and Financial Projection

Last updated: February 10, 2026

Investment Scenario and Fundamentals Analysis for Emtricitabine and Tenofovir Alafenamide Fumarate

Overview

Emtricitabine and tenofovir alafenamide fumarate (TAF) form a combination therapy approved for HIV treatment. Developed by Gilead Sciences, this fixed-dose combination has gained market approval in multiple countries, driven by its efficacy, safety profile, and patient adherence benefits.

Market Position and Demand Drivers

The global HIV therapeutics market was valued at approximately $26 billion in 2022 and is expected to grow at a CAGR of 7.4% through 2028 (source [1]). Emtricitabine/TAF has a key position in this landscape due to:

• Efficacy: Shows comparable or superior viral suppression to earlier nucleoside reverse transcriptase inhibitors (NRTIs)
• Safety Profile: Lower renal toxicity and bone mineral density loss versus tenofovir disoproxil fumarate (TDF)
• Adherence: Once-daily dosing with minimal side effects increases patient compliance
• Patent Exclusivity: Pending or ongoing patent protections extend into the late 2020s or early 2030s in key regions

Competitive Landscape

The drug competes with other fixed-dose combinations (FDCs) such as:

• Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine)
• Triumeq (dolutegravir/abacavir/lamivudine)
• Descovy (emtricitabine/TAF in PrEP formulations)

Gilead's FDC benefits from established manufacturing capacity and existing distribution channels.

Patent and Regulatory Outlook

Patent landscapes indicate primary patent protections for tenofovir alafenamide formulations expire between 2028 and 2030 in major markets (U.S., EU). Gilead holds orphan drug exclusivities and pipeline patent protections that may extend market exclusivity.

Regulatory approvals cover the U.S. (FDA, 2016), EU (EMA, 2016), and Asia-Pacific regions, with ongoing approvals in emerging markets.

Financial and Investment Considerations

• Revenue Contribution: Emtricitabine/TAF contributed roughly $3.2 billion in Gilead’s 2022 revenue, representing ~20% of total sales (source [2])
• Growth Opportunities: Expansion into pre-exposure prophylaxis (PrEP) markets, multi-drug resistance management, and pediatric formulations.
• Pricing Strategy: Premium pricing maintained by Gilead in developed markets, with discounts and tiered pricing in emerging markets.
• R&D Pipeline: Efforts include next-generation formulations, long-acting injectables, and dual therapies targeting resistant HIV strains.

Risks and Challenges

• Patent Cliff: Patent expirations threaten generic competition post-2028.
• Market Competition: Entry of biosimilar and generic versions reduces margins.
• Regulatory Risks: Changes in healthcare policies could impact access and pricing.
• Emerging Alternatives: Long-acting injectables, monoclonal antibodies, or alternative drug classes could reduce demand.

Investment Outlook

The combination's current market dominance and Gilead’s patent protections suggest a stable revenue pipeline through 2028. However, approaching patent expirations and evolving competitor landscape require strategic R&D investments and diversification.

Key Takeaways

• Emtricitabine/TAF secures a leading position in HIV therapy, with a robust revenue stream.
• Patent expirations around 2028–2030 pose significant risks.
• Growth depends on expanding indications, formulations, and geographic reach.
• Competition from generics and biosimilars will pressure margins post-patent expiry.
• Strategic R&D targeting long-acting, resistance-resistant treatments is essential.

FAQs

1. When do patent protections for emtricitabine/TAF expire?
Primarily between 2028 and 2030 in major markets, according to current patent landscapes [3].

2. What factors contribute to the drug's market dominance?
Efficacy, safety profile, adherence benefits, and Gilead's established distribution channels.

3. How does the drug compare to competitors in terms of pricing?
Premium pricing in developed countries; tiered/priced discounts in emerging markets.

4. Are there ongoing R&D efforts for this molecule?
Yes, including long-acting formulations and pediatric versions targeting broader markets.

5. What risks could impact the long-term investment outlook?
Patent expiry, generic competition, regulatory changes, and emergence of alternative technologies.

---

Sources

1. Grand View Research, "HIV Therapeutics Market Size, Share & Trends," 2022.
2. Gilead Sciences Annual Report, 2022.
3. PatentScope, World Intellectual Property Organization, 2023.